Adjusted EBITDA grew 21% in Q2 and 29% year-to-date Cash from operations grew 83% in Q2 and 147% year-to-dateMade principal repayments on the Company's...
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...
VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Prospect Park Capital Corp. (the “Company”) is pleased to announce the following updates:
SECOND QUARTER FINANCIAL RESULTS
VANCOUVER, BC, Aug. 7, 2025 /PRNewswire/ - "Wheaton delivered another outstanding quarter, achieving record revenue, adjusted net earnings, and operating cash...
SECOND QUARTER FINANCIAL RESULTS
VANCOUVER, BC, Aug. 7, 2025 /CNW/ - "Wheaton delivered another outstanding quarter, achieving record revenue, adjusted net earnings, and operating cash...